Clinical Trial

A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 7, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-10; most recent amendment 2026-04-01.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT07301333
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Pain
Enrollment 80 participants
Start Date 2025-12-30
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-07